PROSE治疗儿童Stevens-Johnson综合征相关眼表疾病
配戴PROSE装置时及末次随访最佳矫正视力较初诊显著改善,且多年维持;15例(30.6%)治疗失败。
要点
- 儿童SJS/TEN相关慢性眼表疾病中,PROSE治疗在超过三分之二患者中可行。
- 配戴PROSE装置时BCVA中位数由0.6 logMAR显著改善至0.18 logMAR(P<.0001)。
- 末次随访BCVA中位数维持0.18 logMAR,较初诊显著改善(P=.0004),疗效多年持久。
核心结论
- PROSE治疗在超过三分之二的儿童SJS/TEN相关慢性眼表疾病患者中可行,并带来多年持久的视力显著改善。
主要发现
- SJS/TEN报告病因为抗生素(n=19)、抗癫痫药(n=9)、退热药(n=9)、其他(n=3)、未知(n=9)。
- 疾病起病平均年龄6.4岁,初诊平均年龄9.3岁。
- 初诊BCVA中位数0.6 logMAR(Snellen 20/80),配戴PROSE装置时显著改善至0.18 logMAR(20/30,P<.0001)。
- 末次随访BCVA中位数显著改善至0.18 logMAR(20/30,P=.0004)。
- 15例患者(30.6%)PROSE治疗失败。
关键数值与推荐
- 初诊BCVA中位数0.6 logMAR(20/80 Snellen)。
- 配戴PROSE装置时BCVA中位数0.18 logMAR(20/30 Snellen),P<.0001。
- 末次随访BCVA中位数0.18 logMAR(20/30 Snellen),P=.0004。
- PROSE治疗失败15例,占30.6%。
临床怎么用
- 对儿童SJS/TEN相关慢性眼表疾病,可考虑PROSE治疗以改善并长期维持视力。
- 需注意约30.6%的患儿可能出现PROSE治疗失败。
局限性
- 回顾性、单中心病例系列设计。
- 未设对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the outcomes of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment in pediatric patients with chronic ocular surface disease associated with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). DESIGN: Retrospective, interventional case series. METHODS: Patients aged 18 years or younger seen in consultation for PROSE treatment at a single center between January 1992 and December 2016 with a history of SJS/TEN were reviewed. Demographics, etiology of SJS/TEN, age at treatment milestones, best-corrected visual acuity (BCVA) at treatment milestones, and treatment failures were recorded. BCVA at the initial presentation visit was compared to BCVA at the time of PROSE device dispense and at the last recorded visit. RESULTS: Twenty-seven female and 22 male patients were reviewed. Reported etiology was antibiotic (n = 19), antiepileptic (n = 9), antipyretic (n = 9), other (n = 3), and unknown (n = 9). The mean age was 6.4 years at disease onset and 9.3 years at time of initial presentation. The mean duration of follow-up was 5.45 years. The median BCVA at the initial presentation was 0.6 logMAR (20/80 Snellen), and was significantly improved to 0.18 logMAR (20/30 Snellen) at the time a PROSE device was dispensed (P < .0001). The median BCVA at the last recorded visit was significantly improved to 0.18 logMAR (20/30 Snellen, P = .0004). There were 15 patients who failed PROSE treatment (30.6%). CONCLUSIONS: PROSE treatment is feasible in over two thirds of pediatric patients with chronic ocular surface disease related to SJS/TEN and results in significant improvement in vision that is durable over a period of many years.
引用
- Wang Y, Rao R, Jacobs DS, et al. Prosthetic Replacement of the Ocular Surface Ecosystem Treatment for Ocular Surface Disease in Pediatric Patients With Stevens-Johnson Syndrome. Am J Ophthalmol. 2019. PMID: 30664843. doi:10.1016/j.ajo.2019.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。